Shire’s Lialda, Gattex are hedge funder’s latest patent targets

Tracy Staton

fund manager Kyle Bass has struck out at drug patents once again. Just weeks after challenging two patents on an Acorda Therapeutics drug, Bass asked the U.S. and Trademark Office to reconsider coverage on two Shire meds, and .

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS